Analysts forecast 30% lower net profit.
Hikma will supply the antipsychotic drug in the MENA region.
Monthly survey results published.
Company informs Hungary's leading pharma co. on Wednesday.
Green-light by FDA warmly welcomed.
Richter to supply, Seqirus to sell.
Midcaps remain appealing.
Revenues and profit overshoot estimates.
Earnings report to be released on 10 May.
Mol chief Hernádi to be Chairman of Board of Trustees.
Dividend in focus.
The rating is 'overweight'.
Via convertible notes.
From 2018 profits. Invitation for AGM shows.
One-off item dents profits.
Richter to publish Q4 2018 earnings report this week.
New technical director to be appointed.
With Dutch Pantarhei Bioscience on sale of combined oral contraceptive.
Recommendation remains 'Hold', though.
Drop in Esmya sales weigh on results.